Capricor seeks U.S. marketing nod for DMD drug Seeking Alpha
| CAPR Stock | USD 13.86 0.36 2.53% |
Slightly above 63% of Capricor Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Capricor Therapeutics suggests that many traders are alarmed. Capricor Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Capricor Therapeutics. Many technical investors use Capricor Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Capricor |
Capricor Therapeutics stock gains as the company completes the U.S. marketing application for lead drug deramiocel in Duchenne muscular dystrophy. Read more here.
Read at seekingalpha.com
 |
Capricor Therapeutics Fundamental Analysis
We analyze Capricor Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Capricor Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Capricor Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Retained Earnings
Retained Earnings Comparative Analysis
Capricor Therapeutics is currently under evaluation in retained earnings category among its peers. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
Capricor Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Capricor Therapeutics stock to make a market-neutral strategy. Peer analysis of Capricor Therapeutics could also be used in its relative valuation, which is a method of valuing Capricor Therapeutics by comparing valuation metrics with similar companies.
Peers
Capricor Therapeutics Related Equities
| MGTX | MeiraGTx Holdings | 0.16 | ||||
| MBRX | Moleculin Biotech | 0.56 | ||||
| IDYA | Ideaya Biosciences | 2.24 | ||||
| ANAB | AnaptysBio | 3.17 | ||||
| SLNO | Soleno Therapeutics | 3.68 | ||||
| PULM | Pulmatrix | 4.31 | ||||
| NXTC | NextCure | 4.49 | ||||
| UNCY | Unicycive Therapeutics | 5.13 | ||||
| KROS | Keros Therapeutics | 6.00 | ||||
| PHIO | Phio Pharmaceuticals | 6.63 | ||||
| CDTX | Cidara Therapeutics | 7.85 | ||||
| BPTH | Bio Path | 8.41 | ||||
| AKTX | Akari Therapeutics | 9.22 |
Additional Tools for Capricor Stock Analysis
When running Capricor Therapeutics' price analysis, check to measure Capricor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Capricor Therapeutics is operating at the current time. Most of Capricor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Capricor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Capricor Therapeutics' price. Additionally, you may evaluate how the addition of Capricor Therapeutics to your portfolios can decrease your overall portfolio volatility.